Danicopan for COVID-19: real-time analysis

Download Image

Post

c19early.org

Danicopan for COVID-19

1 study with 201 patients

Serious outcome risk

Danicopan

Control

COVID-19 Danicopan studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−43%

Mortality (1)−43%

Hospitalization (1)−19%

RCTs (1)−43%

Late (1)−43%

00.511.5+

← Danicopan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Apr 23 2022	Beigel et al., NCT04988035	ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
Apr 23 2022	43% higher mortality (p=0.34), 17% higher ventilation (p=0.69), 54% worse recovery (p=0.01), and 37% worse improvement (p=0.06). RCT 201 hospitalized COVID-19 patients showing increased risk with danicopan treatment, with statistical significance for time to sustained recovery.